

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CD8

RRID:AB_2738030

Type: Antibody

Proper Citation

BD Biosciences Cat# 563152, RRID:AB_2738030

Antibody Information

URL: http://antibodyregistry.org/AB_2738030

Proper Citation: BD Biosciences Cat# 563152, RRID:AB_2738030

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD8

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: 53-6.7

Antibody ID: AB_2738030

Vendor: BD Biosciences

Catalog Number: 563152

Record Creation Time: 20231110T033529+0000

Record Last Update: 20260901T011443+0000

Ratings and Alerts

No rating or validation information has been found for CD8.

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tong T, et al. (2026) Microbial metabolite FAD mobilizes adipocyte lipid remodeling to enhance cancer immunotherapy efficacy. *Cell metabolism*, 38(3), 565.

Li J, et al. (2026) Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity. *Cancer cell*.

Hu M, et al. (2025) Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype. *Cell reports*, 44(5), 115589.

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. *The Journal of pharmacology and experimental therapeutics*, 392(8), 103634.

Chen XY, et al. (2024) Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer. *iScience*, 27(11), 111148.

Franzolin G, et al. (2024) PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination. *Cancer immunology research*, 12(9), 1286.

Wang Z, et al. (2024) CRISPR-Cas9 screening identifies INTS3 as an anti-apoptotic RNA-binding protein and therapeutic target for colorectal cancer. *iScience*, 27(5), 109676.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. *Cell*, 187(18), 4905.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. *Cell*, 187(11), 2690.

Régnier P, et al. (2023) FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis. *Cell reports. Medicine*, 4(12), 101256.

McCauley KE, et al. (2022) Heritable vaginal bacteria influence immune tolerance and relate to early-life markers of allergic sensitization in infancy. *Cell reports. Medicine*, 3(8), 100713.

Wang B, et al. (2021) CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell. *Journal for immunotherapy of cancer*, 9(8).

Costa FRC, et al. (2021) NLRP1 acts as a negative regulator of Th17 cell programming in mice and humans with autoimmune diabetes. Cell reports, 35(8), 109176.

Calvo-Barreiro L, et al. (2021) Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(2), 920.